Generate Biomedicines, Inc.
GENB
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.22M | 8.82M | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.22M | 8.82M | |||
| Cost of Revenue | 57.81M | 46.83M | |||
| Gross Profit | -50.59M | -38.01M | |||
| SG&A Expenses | 13.52M | 10.15M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 71.34M | 56.97M | |||
| Operating Income | -64.11M | -48.15M | |||
| Income Before Tax | -61.69M | -44.26M | |||
| Income Tax Expenses | 28.00K | 56.00K | |||
| Earnings from Continuing Operations | -61.71M | -44.31M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 268.00K | 2.63M | |||
| Net Income | -61.45M | -41.69M | |||
| EBIT | -64.11M | -48.15M | |||
| EBITDA | -63.04M | -46.84M | |||
| EPS Basic | -1.07 | -1.62 | |||
| Normalized Basic EPS | -0.59 | -0.76 | |||
| EPS Diluted | -1.07 | -1.62 | |||
| Normalized Diluted EPS | -0.59 | -0.76 | |||
| Average Basic Shares Outstanding | 64.87M | 32.79M | |||
| Average Diluted Shares Outstanding | 64.87M | 32.79M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||